Evidence map›Paper›PMID 30223985›Full record

Trial reportThe Lancet. Global health2018

Feasibility and safety of mass drug coadministration with azithromycin and ivermectin for the control of neglected tropical diseases: a single-arm intervention trial.

Lucia Romani, Michael Marks, Oliver Sokana, Titus Nasi, Bakaai Kamoriki, Handan Wand, Margot J Whitfeld, Daniel Engelman, Anthony W Solomon, Andrew C Steer and 1 more

Erratum issuedOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in The Lancet. Global health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Trial
  5. Article
  6. Scabies.Nature reviews. Disease primers · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Costs of mass drug administration for scabies in Fiji.PLoS neglected tropical diseases · 2022
    Article
  15. Article
  16. Review
  17. Review
  18. Paediatrics: how to manage scabies.Drugs in context · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Lucia RomaniThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia; Murdoch Children's Research Institute, Melbourne, VIC, Australia. Electronic address: lromani@kirby.unsw.edu.au.
Michael MarksClinical Research Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Hospital for Tropical Diseases, London, UK.
Oliver SokanaMinistry of Health and Medical Services, Honiara, Solomon Islands.
Titus NasiMinistry of Health and Medical Services, Honiara, Solomon Islands.
Bakaai KamorikiMinistry of Health and Medical Services, Honiara, Solomon Islands.
Handan WandThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Margot J WhitfeldSt Vincent's Hospital Sydney, Sydney, NSW, Australia.
Daniel EngelmanMurdoch Children's Research Institute, Melbourne, VIC, Australia; Centre for International Child Health, University of Melbourne, Melbourne, VIC, Australia.
Anthony W SolomonClinical Research Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Andrew C SteerMurdoch Children's Research Institute, Melbourne, VIC, Australia; Centre for International Child Health, University of Melbourne, Melbourne, VIC, Australia.
John M KaldorThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
UNSW Sydney · AULondon School of Hygiene & Tropical Medicine · GBMurdoch Children's Research Institute · AUSt Vincent's Hospital Sydney · AU

Funding

Wellcome TrustWellcome Trust 098521Wellcome Trust 102807World Health Organization 001
6 · The paper itself

Abstract

backgroundMass drug administration has made a major contribution to the public health control of several important neglected tropical diseases. For settings with more than one endemic disease, combined mass drug administration has potential practical advantages compared with separate programmes but needs confirmation of feasibility and safety. We undertook a study of mass drug administration in the Solomon Islands for trachoma and scabies control using ivermectin and azithromycin, key drugs in the control of neglected tropical diseases worldwide.

methodsThe entire population of Choiseul province, Solomon Islands, was eligible to participate. An azithromycin-based mass drug administration regimen was offered in line with standard recommendations for trachoma elimination (oral azithromycin or topical tetracycline). An ivermectin-based mass drug administration regimen was offered at the same time (oral ivermectin or topical permethrin), with a further dose 7-14 days later, using a modified version of a regimen demonstrated to be effective for scabies control. All participants underwent safety assessments 7-14 days later. Participants in ten randomly selected sentinel villages underwent a more detailed safety assessment. Routine health system reports of hospital or clinic admissions and deaths were also obtained to compare health outcomes in the 12 month period before and after the mass drug administration.

findingsThe study enrolled 26 188 participants, 99·3% of the estimated resident population as determined at the 2009 census. Of those enrolled, 25 717 (98·2%) received the trachoma regimen and 25 819 (98·6%) received the first dose of the scabies regimen between Sept 1, and Oct 2, 2015. A second dose of the scabies regimen was received by 21 931 (83·7%) of participants. Adverse events, all mild and transient, were recorded in 571 (2·6%) of the entire study population and 58 (4·1%) of participants in the ten sentinel villages. In the 12 months before and after the mass drug administration the numbers of hospital admissions (1530 vs 1602) and deaths (73 vs 83) were similar. In the month after the mass drug administration, 84 individuals were admitted to hospital and two died, compared with a monthly median of 116 admissions (IQR 106-159) and six deaths (IQR 4-7) in the 12 months before and after the mass drug administration.

interpretationIn the largest trial so far involving coadministration of regimens based on ivermectin and azithromycin, the combination was safe and feasible in a population of more than 26 000 people. Coadministration of mass drug administration based on these two drugs opens up new potential for the control of neglected tropical diseases.

fundingInternational Trachoma Initiative, Murdoch Children's Research Institute, Scobie and Claire Mackinnon Trust, Wellcome Trust.

Indexed as

Mass Drug AdministrationAdministration, OralAdministration, TopicalAdolescentAdultAnti-Bacterial AgentsAzithromycinChildChild, PreschoolDrug Therapy, CombinationEndemic DiseasesFeasibility StudiesFemaleHumansInfantInfant, NewbornAnti-Bacterial AgentsAzithromycinIvermectinTetracycline

Identifiers

PMID30223985
PMCPMC6139784
OpenAlexW2891534801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.